2.1. Study Population and Design
malignancy
A subset of 38 patients from a Phase I, multicenter, open-label, dose-escalation study of mitazalimab in patients with failed standard treatment for confirmed advanced or refractory solid malignancy (ClinicalTrials.gov: NCT02829099; Eudra CT: 2016–000969-23), was selected for analysis using RNA sequencing. The study design and the results of the clinical trial have previously been reported [